A Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma
ID Number 13-1457Principal Investigator(s)
Krzysztof J. Misiukiewicz
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to determine the safety and effectiveness of a drug called ON 01910.Na when given to people with HPV positive or negative SCC.
Recruiting Patients: Yes